Insilico Medicine, a global leader in artificial intelligence–driven drug discovery, has entered into a multi-year research and development collaboration with Servier, an independent international pharmaceutical company governed by a foundation. The partnership aims to identify and develop novel therapies for difficult-to-treat oncology targets by leveraging Insilico’s proprietary AI platform, Pharma.AI.

Under the terms of the agreement, Insilico is eligible to receive up to USD 32 million in upfront and near-term R&D payments. Insilico will lead the AI-enabled discovery and development of drug candidates that meet predefined criteria, while Servier will share R&D costs and take responsibility for clinical validation and commercialisation.

The collaboration reflects Servier’s strategy to integrate advanced technologies into its research efforts to address unmet medical needs in cancer care. Servier will apply its clinical development and global commercial expertise to advance successful candidates emerging from the programme.

Insilico brings significant experience in AI-driven oncology drug discovery, with a broad pipeline spanning multiple cancer indications. Among its most advanced assets are the potential best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both of which are currently in global, multicentre phase I clinical trials. In addition, four other oncology programmes have been fully or partially out-licensed to partners, with phase I studies underway.

By combining artificial intelligence, automation, and advanced computational modelling, Insilico has markedly improved the efficiency of early-stage drug development. While traditional discovery timelines typically average around 4.5 years, Insilico has nominated 20 preclinical candidates between 2021 and 2024, achieving an average timeline of 12 to 18 months from project initiation to preclinical candidate nomination. Each programme required the synthesis and testing of only 60 to 200 molecules.

Insilico Medicine is a global biotechnology company focused on integrating AI and automation across the drug discovery and development lifecycle, with the aim of accelerating innovation in the life sciences and improving patient outcomes worldwide.